177Lu-PSMA转移性去势抵抗前列腺癌的治疗后剂量测定：来自泰国两所大学医院的经验

IF 1.6 4区医学 Q4 ONCOLOGY

Asia-Pacific journal of clinical oncology Pub Date : 2025-05-21 DOI:10.1111/ajco.14187

Onnicha Pattanawong, Putthiporn Charoenphun, Wichana Chamroonrat, Thonnapong Thongpraparn, Nucharee Poon-Iad, Benjapa Khiewvan, Krisanat Chuamsaamarkkee

{"title":"177Lu-PSMA转移性去势抵抗前列腺癌的治疗后剂量测定：来自泰国两所大学医院的经验","authors":"Onnicha Pattanawong, Putthiporn Charoenphun, Wichana Chamroonrat, Thonnapong Thongpraparn, Nucharee Poon-Iad, Benjapa Khiewvan, Krisanat Chuamsaamarkkee","doi":"10.1111/ajco.14187","DOIUrl":null,"url":null,"abstract":"Objective: 177Lu-PSMA radioligand therapy (RLT) is increasingly used to treat metastatic castration-resistant prostate cancer (mCRPC). Posttreatment dosimetry is essential for assessing normal organ absorbed doses. Therefore, this study aims to evaluate normal organs dosimetry in mCRPC patients undergoing 177Lu-PSMA-RLT from two university-based hospitals in Thailand.Methods: We retrospectively analyzed 61 treatment cycles in 36 patients who underwent posttreatment whole-body planar imaging at three time points (1, 24, and 168 h postadministration). Absorbed doses were computed using organ based MIRD (Medical Internal Radiation Dosimetry) method with OLINDA/EXM v.2.2 in Hermes dosimetry software.Results: The median treated activity was 5.79 GBq (range 5.00-7.29 GBq). Normal organ absorbed doses, from lowest to highest, were red marrow (0.03 ± 0.03 Gy/GBq), total body (0.04 ± 0.03 Gy/GBq), liver (0.13 ± 0.33 Gy/GBq), salivary glands (0.65 ± 0.42 Gy/GBq), and kidneys (0.72 ± 0.36 Gy/GBq).Conclusion: Absorbed doses to normal organs remained within an acceptable range and not exceed the tolerance limits.","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Post-Therapeutic Dosimetry of Metastatic Castration-Resistant Prostate Cancer With 177Lu-PSMA: Experiences From Two University-Based Hospitals in Thailand.\",\"authors\":\"Onnicha Pattanawong, Putthiporn Charoenphun, Wichana Chamroonrat, Thonnapong Thongpraparn, Nucharee Poon-Iad, Benjapa Khiewvan, Krisanat Chuamsaamarkkee\",\"doi\":\"10.1111/ajco.14187\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: 177Lu-PSMA radioligand therapy (RLT) is increasingly used to treat metastatic castration-resistant prostate cancer (mCRPC). Posttreatment dosimetry is essential for assessing normal organ absorbed doses. Therefore, this study aims to evaluate normal organs dosimetry in mCRPC patients undergoing 177Lu-PSMA-RLT from two university-based hospitals in Thailand.Methods: We retrospectively analyzed 61 treatment cycles in 36 patients who underwent posttreatment whole-body planar imaging at three time points (1, 24, and 168 h postadministration). Absorbed doses were computed using organ based MIRD (Medical Internal Radiation Dosimetry) method with OLINDA/EXM v.2.2 in Hermes dosimetry software.Results: The median treated activity was 5.79 GBq (range 5.00-7.29 GBq). Normal organ absorbed doses, from lowest to highest, were red marrow (0.03 ± 0.03 Gy/GBq), total body (0.04 ± 0.03 Gy/GBq), liver (0.13 ± 0.33 Gy/GBq), salivary glands (0.65 ± 0.42 Gy/GBq), and kidneys (0.72 ± 0.36 Gy/GBq).Conclusion: Absorbed doses to normal organs remained within an acceptable range and not exceed the tolerance limits.\",\"PeriodicalId\":8633,\"journal\":{\"name\":\"Asia-Pacific journal of clinical oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-05-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asia-Pacific journal of clinical oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/ajco.14187\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajco.14187","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：lu - psma放射配体治疗（RLT）越来越多地用于治疗转移性去势抵抗性前列腺癌（mCRPC）。治疗后剂量测定对于评估正常器官吸收剂量是必不可少的。因此，本研究旨在评估泰国两所大学医院接受177Lu-PSMA-RLT的mCRPC患者的正常器官剂量学。方法：我们回顾性分析了36例患者的61个治疗周期，这些患者在治疗后3个时间点（给药后1、24和168小时）接受了全身平面成像。使用Hermes剂量测定软件中的OLINDA/EXM v.2.2使用基于器官的MIRD（医学内辐射剂量测定）方法计算吸收剂量。结果：治疗后活性中位数为5.79 GBq（范围5.00-7.29 GBq）。正常器官吸收剂量从低到高依次为：红骨髓（0.03±0.03 Gy/GBq）、全身（0.04±0.03 Gy/GBq）、肝脏（0.13±0.33 Gy/GBq）、唾液腺（0.65±0.42 Gy/GBq）、肾脏（0.72±0.36 Gy/GBq）。结论：正常器官的吸收剂量保持在可接受范围内，不超过耐受限度。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Post-Therapeutic Dosimetry of Metastatic Castration-Resistant Prostate Cancer With ¹⁷⁷Lu-PSMA: Experiences From Two University-Based Hospitals in Thailand.

Objective: ¹⁷⁷Lu-PSMA radioligand therapy (RLT) is increasingly used to treat metastatic castration-resistant prostate cancer (mCRPC). Posttreatment dosimetry is essential for assessing normal organ absorbed doses. Therefore, this study aims to evaluate normal organs dosimetry in mCRPC patients undergoing ¹⁷⁷Lu-PSMA-RLT from two university-based hospitals in Thailand.

Methods: We retrospectively analyzed 61 treatment cycles in 36 patients who underwent posttreatment whole-body planar imaging at three time points (1, 24, and 168 h postadministration). Absorbed doses were computed using organ based MIRD (Medical Internal Radiation Dosimetry) method with OLINDA/EXM v.2.2 in Hermes dosimetry software.

Results: The median treated activity was 5.79 GBq (range 5.00-7.29 GBq). Normal organ absorbed doses, from lowest to highest, were red marrow (0.03 ± 0.03 Gy/GBq), total body (0.04 ± 0.03 Gy/GBq), liver (0.13 ± 0.33 Gy/GBq), salivary glands (0.65 ± 0.42 Gy/GBq), and kidneys (0.72 ± 0.36 Gy/GBq).

Conclusion: Absorbed doses to normal organs remained within an acceptable range and not exceed the tolerance limits.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Asia-Pacific journal of clinical oncology 医学-肿瘤学

CiteScore

3.40

自引率

0.00%

发文量

175

审稿时长

6-12 weeks

期刊介绍： Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.